Clinical and Quality-of-Life Outcomes of Omalizumab Treatment in Chronic Spontaneous Urticaria

Abstract

Aims
To evaluate response to omalizumab in chronic spontaneous urticaria (CSU), assess concordance between symptom and quality-of-life scores, and identify predictors of response.

Methods
Single-centre retrospective review of adults with CSU treated with omalizumab in a dermatology department in the Midwest of Ireland. Data included demographics, disease duration, and baseline and latest Urticaria Severity Score (USS), Dermatology Life Quality Index (DLQI), and itch and rash scores. Responders were defined as ≥50% USS improvement. Associations were analysed using Spearman’s correlation and Cohen’s κ.

Results
Thirty-six patients were included; 22 (61%) responded, including 11 complete responders. Complete responders had lower baseline USS and DLQI. Correlations between USS and other measures were moderate, with slight–moderate agreement.

Discussion
Omalizumab improved CSU outcomes. Lower baseline severity predicted complete response, while symptom and quality-of-life improvements showed limited individual concordance.